Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion type Assertion NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_head.
- NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_provenance.
- NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion evidence source_evidence_literature NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_provenance.
- NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion SIO_000772 22895556 NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_provenance.
- NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion wasDerivedFrom befree-20150227 NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_provenance.
- NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_assertion wasGeneratedBy ECO_0000203 NP606023.RAKwln6NElLXBIGUb2PMDImsGhJ0KxwXle5NuDj1O0De8130_provenance.